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Proliferative diabetic retinopathy (PDR), a condi-
tion characterized by aberrant angiogenesis in the eye, is 
among the most common and devastating complications of 
diabetes mellitus and the most frequent cause of blindness in 
working-age adults in the United States [1-3]. The aberrant 
vessels in PDR often grow into the vitreous, are leaky, prone 
to hemorrhage, and can lead to the formation of epiretinal 
fibrovascular membranes (FVMs) and subsequent tractional 
or combined tractional and rhegmatogenous retinal detach-
ment, for which surgery is indicated to avoid permanent 
vision loss [4,5]. Substantial evidence indicates that vascular 
endothelial growth factor (VEGF) induction plays a crucial 
role in PDR [6-9]. However, anti-VEGF therapy is rarely used 
in PDR because this therapy may trigger hemorrhage and 
retinal detachment [10-14]. Other treatments for PDR include 
pan-retinal photocoagulation and surgical removal of the 
FVMs, though these treatments are not without complica-
tions. Pan-retinal photocoagulation may lead to peripheral 
vision loss, and additional surgical procedures involve high 
risk in patients with advanced diabetes [15].
A significant barrier for progress in the field is that 
animal models of diabetes do not develop PDR [16-19]. 
The available animal models mostly reproduce early-stage 
DR pathological features including pericyte loss, acellular 
capillaries, and microaneurysms [20-24]. Thus, PDR patho-
biology is usually studied using surrogate models such as 
oxygen-induced retinopathy and choroidal neovascularization 
[25-28]. Moreover, currently available in vitro models involve 
short-term culture of vascular cells under high-glucose condi-
tions that only partially reproduce the diabetic milieu [29]. As 
these cultures are often derived from non-diabetic donors, 
the cultures also lack environmental and genetic factors 
that could be important for the disease. Specifically, cells 
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Purpose: Epiretinal fibrovascular membranes (FVMs) are a hallmark of proliferative diabetic retinopathy (PDR). Surgi-
cal removal of FVMs is often indicated to treat tractional retinal detachment. This potentially informative pathological 
tissue is usually disposed of after surgery without further examination. We developed a method for isolating and char-
acterizing cells derived from FVMs and correlated their expression of specific markers in culture with that in tissue.
Methods: FVMs were obtained from 11 patients with PDR during diabetic vitrectomy surgery and were analyzed with 
electron microscopy (EM), comparative genomic hybridization (CGH), immunohistochemistry, and/or digested with 
collagenase II for cell isolation and culture. Antibody arrays and enzyme-linked immunosorbent assay (ELISA) were 
used to profile secreted angiogenesis-related proteins in cell culture supernatants.
Results: EM analysis of the FVMs showed abnormal vessels composed of endothelial cells with large nuclei and plasma 
membrane infoldings, loosely attached perivascular cells, and stromal cells. The cellular constituents of the FVMs 
lacked major chromosomal aberrations as shown with CGH. Cells derived from FVMs (C-FVMs) could be isolated and 
maintained in culture. The C-FVMs retained the expression of markers of cell identity in primary culture, which define 
specific cell populations including CD31-positive, alpha-smooth muscle actin-positive (SMA), and glial fibrillary acidic 
protein-positive (GFAP) cells. In primary culture, secretion of angiopoietin-1 and thrombospondin-1 was significantly 
decreased in culture conditions that resemble a diabetic environment in SMA-positive C-FVMs compared to human 
retinal pericytes derived from a non-diabetic donor.
Conclusions: C-FVMs obtained from individuals with PDR can be isolated, cultured, and profiled in vitro and may 
constitute a unique resource for the discovery of cell signaling mechanisms underlying PDR that extends beyond current 
animal and cell culture models.
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from diabetic sources have been shown to have “metabolic 
memory,” implicating potential epigenetic changes from 
continual exposure to a high-glucose environment [30,31]. To 
address the need for new experimental platforms that allow 
for the discovery of novel cell signaling mechanisms linked 
to PDR, we developed a methodology for isolation and culture 
of cells from patient-derived FVMs.
Recently, a population of cells negative for endothelial 
cell markers (CD31 and VEGFR2) and partially positive for 
hematopoietic (CD34, CD47) and mesenchymal stem cell 
markers (CD73, CD90/Thy-1, and PDGFR-β) was cultured ex 
vivo from epiretinal membranes from patients and compared 
to RPE cells [32]. In this study, we report on the evaluation 
of FVM morphology, subsequent isolation, characterization, 
and primary culture of CD31-positive and alpha-smooth 
muscle actin-positive cells from FVMs obtained directly 
from patients undergoing surgery for PDR.
METHODS
Study population: Eleven patients were recruited from Massa-
chusetts Eye and Ear and Dean McGee Eye Institute. Seven 
patients had type 1 diabetes mellitus, while four patients had 
type 2 diabetes mellitus. All patients were medically cleared 
for surgery. Six subjects were male, and five subjects were 
female. The mean age was 41.7 years old, with ages ranging 
from 28 to 59 years old. This study was performed at the 
Schepens Eye Research Institute/ Massachusetts Eye and 
Ear. Research protocols were approved by the Institutional 
Review Board at Massachusetts Eye and Ear for the collection 
of surgical specimens and for the retrospective analysis of the 
clinical data. Similarly, Institutional Review Board approval 
was also obtained from the Dean McGee Eye Institute at the 
University of Oklahoma Medical Center to collect additional 
surgical and blood specimens. All research protocols adhered 
to the tenets of the Declaration of Helsinki [33], and each 
patient signed a consent form and Health Information Porta-
bility and Accountability Act (HIPAA) authorization before 
participation within the study. All research protocols adhere 
to the ARVO statement on human subjects and to the tenets of 
the Declaration of Helsinki [33]. Each patient signed a consent 
form and Health Information Portability and Accountability 
Act (HIPAA) authorization before participation within the 
study.
Patients were selected and included in the study if they 
presented with active fibrovascular proliferation due to PDR 
with retinal detachment or vitreous hemorrhage not amenable 
to observation or further treatment with pan-retinal photo-
coagulation. Patients were excluded from the study if they 
were under the age of 18, pregnant, not medically stable for 
surgery, or had a history of previous penetrating eye trauma. 
The patients’ records were obtained and reviewed to record 
demographic and clinical data. Fundus photography was 
performed with Optos wide field imaging (Optos, Scotland, 
UK) where indicated and possible. Blood was drawn from 
all study participants through venipuncture for comparative 
genomic hybridization. Blood was drawn from subject with 
standard methods for venipuncture into EDTA collection 
tubes, and immediately stored at 4 °C. Genomic DNA was 
isolated from blood using a Qiagen DNeasy Blood and Tissue 
Kit (Qiagen, Valencia, CA). Blood samples from the Univer-
sity of Oklahoma were delivered at room temperature using 
overnight mail.
All patients underwent standard 23-gauge three-port pars 
plana vitrectomy using a combination of delamination and 
segmentation techniques with intraocular forceps, scissors, 
and a vitrector. Extensive panretinal photocoagulation using 
endolaser was performed on all patients. Retinal tamponade 
was performed with non-expansile C3F8 gas or silicone oil. 
Control retina samples were obtained from cadaver eyes 
through an approved Institutional Review Board protocol 
from Massachusetts General Hospital.
Processing of surgically-removed FVMs: Immediately after 
surgery, the FVMs were placed in ice-cold calcium-free and 
magnesium-free Hank’s balanced salt solution for transporta-
tion. Membranes were divided into pieces and processed for 
electron microscopy, immunohistochemistry, or cell culture. 
The size of the FVM tissue recovered during surgery was 
a limiting factor that determine the number of procedures 
and studies conducted in each sample. The FVM samples 
obtained from the University of Oklahoma were shipped on 
dry ice and used for genetic studies only.
Immunohistochemistry: FVMs and samples of control retinas 
were fixed in 10% formalin in Dulbecco’s PBS (1X; 137 mM 
NaCl, 2.7 mM KCl, 8 mM Na2PO4, 1.47 mM KH2PO4, pH 7.4) 
overnight at room temperature and stored in PBS at 4 °C until 
paraffin embedding. Serial sections (6 μm) were cut, deparaf-
finized in 100% xylene, rehydrated in a series of ethanol, and 
washed in PBS. Sections were processed for immunohisto-
chemistry using the following antibodies: CD31 (1:50; Dako, 
Carpinteria, CA), alpha-smooth muscle actin (SMA, 1:50; 
Dako), glial fibrillary acidic protein (GFAP, 1:500; Dako), 
retinal pigment epithelium-specific protein 65 (RPE65, 1:250; 
Chemicon, Billerica, MA), bestrophin-1 (BEST-1, 1:150; 
Abcam, Cambridge, MA), and Ki67 (1:50; Novus Biologicals, 
Littleton, CO). Heat-induced epitope retrieval, as recom-
mended by the manufacturer, was performed in either boiling 
citrate buffer (pH 6) for RPE65, BEST-1, and Ki67 or boiling 
Tris-EDTA buffer (pH 9) for CD31 and SMA; proteinase 
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K was used as the antigen retrieval method for GFAP. The 
slides were then incubated in 3% H2O2 in methanol to block 
endogenous peroxidases and then blocked in protein blocking 
solution and incubated in primary antibody overnight at 4 °C. 
The following day, sections were incubated in a biotinylated 
secondary antibody for 1 h followed by alkaline phosphatase-
conjugated avidin (Vectastain ABC-AP Universal Kit; Vector 
Laboratories, Burlingame, CA) for 30 min and then visual-
ized with the Vector Red chromogenic substrate kit (SK-5100; 
Vector Laboratories). For the Ki67 samples, tyramide signal 
amplification (TSA, PerkinElmer, Waltham, MA) was 
performed following incubation in biotinylated secondary 
antibody, and the Vector Red chromogenic substrate was 
added. Finally, the slides were counterstained with Gill no. 
3 hematoxylin (Sigma-Aldrich, St. Louis, MO), and cover-
slips were mounted with Permount medium (Thermo Fisher 
Scientific, Waltham, MA) before imaging using an Axioskop 
2 MOT Plus microscope (Carl Zeiss Inc., Thornwood, NY).
Cellularity and staining for CD31, SMA, GFAP, RPE65, 
BEST-1, and Ki67 within the FVMs were analyzed by quanti-
fying the number of nuclei and the number of marker-positive 
cells using ImageJ (Version 1.47; NIH, Bethesda, MD). Since 
the number of nuclei was quantified in sections for each 
marker, the number of nuclei is presented as the average for 
each individual case. To standardize for the size differences 
in FVMs obtained from different patients, ImageJ was used to 
measure the area of each FVM on the same section for which 
counts of marker-positive cells were performed. Results are 
expressed as the number of CD31, SMA, GFAP, RPE65, and 
BEST-1-positive cells per 10 µm2. Ki67 data are expressed as 
a percentage of the positive cells to match the format of the 
data obtained from the Muse flow cytometry analyzer.
Cell isolation and culture of C-FVMs: With the aid of 
a dissecting microscope, FVMs were transferred into 
500 µl PBS buffer containing 1021 Unit/ml collagenase II 
(Worthington, Lakewood, NY) and 0.25% bovine calf serum 
(Hyclone, Logan, UT) and incubated at 37 °C for 60 min. 
Subsequently, the C-FVMs were washed once in Dulbecco’s 
modified Eagle’s medium (DMEM; Lonza, Walkersville, 
MD) containing 1% L-glutamine, 5% bovine calf serum 
(Hyclone), 2.5% weight/vol nystatin, 100 U/ml penicillin 
G, and 100 mg/ml streptomycin by brief centrifugation. 
FVM cells were resuspended in 250 μl of FVM medium 
that consisted of endothelial basal medium 2 (EBM2; 
Lonza) supplemented with the endothelial cell growth media 
(EGM-2) Bullet Kit (Lonza), 100 U/ml penicillin, 100 mg/
ml of streptomycin (Lonza), 2 mM of L-glutamine (Lonza), 
12% fetal bovine serum (FBS; final concentration obtained 
by adding the serum aliquot included with the EGM-2 Bullet 
Kit and additional fetal bovine serum; Atlanta Biologicals, 
Flowery Branch, GA), and 15 mM D-glucose (final concentra-
tion obtained by supplementing the 5 mM D-glucose already 
present in the EBM2 with additional D-glucose purchased 
from Sigma) and seeded onto culture plates coated with 0.2% 
gelatin in PBS.
Isolation of CD31-positive cells: Single-cell suspensions of 
the C-FVMs prepared as described earlier were incubated 
with 20 μl of CD31 Dynabeads (Invitrogen Dynal AS, 
Oslo, Norway) in PBS containing 2% FBS, mixed gently, 
and placed on a shaker (Barnstead/Thermolyne, Dubuque, 
IA) at 4 °C for 15 min. CD31-positive cells were isolated 
by using the beads via a magnetic rack and washed twice 
with PBS containing 2% FBS. The CD31-positive cells were 
resuspended in 250 μl culture medium that consisted of FVM 
medium supplemented with VEGF to a final concentration 
of 6 ng/ml and seeded onto a culture plate previously coated 
with 1% laminin and 1% collagen Type I in PBS.
Immunofluorescence: C-FVMs were seeded on a four-well 
Chamber Slide System (Thermo Fisher Scientific). Cells were 
fixed with 4% paraformaldehyde for 10 min, permeabilized 
with 0.25% Triton X-100 in PBS for 5 min, and blocked (10% 
goat serum in PBS) for 1 h. To identify smooth muscle cells 
and myofibroblasts, cultures were incubated with a fluo-
rescein isothiocyanate (FITC)-conjugated monoclonal anti-
SMA primary antibody (1:150; Sigma). To label astrocytes 
and glial cells, cells were incubated with a rabbit polyclonal 
anti-GFAP primary antibody (1:150; Dako) overnight at 4 °C 
followed by incubation with goat anti-rabbit Alexa Fluor 488 
secondary antibody (1:200; Life Technologies, Carlsbad, CA) 
for 2 h at room temperature. CD31 staining was performed 
using a similar procedure with the CD31 primary antibody 
(1:50; Dako, Carpinteria, CA) and anti-mouse Alexa Fluor 
647 secondary antibody (1:200; Life Technologies, Carlsbad, 
CA). Isolectin B4 staining was performed using isolectin B4 
primary antibody directly conjugated to Alexa Fluor 648 
(1:100, Invitrogen, Carlsbad, CA). Coverslips were mounted 
onto the chamber slides using a Prolong Gold antifade reagent 
with 4’,6-diamidino-2-phenylindole (DAPI; Life Technolo-
gies). Images were obtained using a Zeiss Axioskop 2 MOT 
Plus microscope (Carl Zeiss Inc.).
Muse f low cytometry analysis: Cell proliferation of the 
C-FVMs from clinical cases 3 and 5 were determined using 
the Muse Ki67 Proliferation Kit (EMD Millipore, Hayward, 
CA). Passage 4–6 cells were plated in a 12-well plate and 
treated with a standard growth medium consisting of FVM 
medium or the same media that did not contain FBS or the 
EGM Bullet Kit (growth factor deprivation medium). Cells 
were harvested using trypsin and resuspended in PBS at a 
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cellular concentration of 5.0 × 105 cells/ml. The cell suspen-
sions were washed, pelleted, resuspended in 50 µl of fixative 
solution, and incubated at room temperature for 15 min. The 
samples were then washed and incubated in permeabilization 
buffer for 15 min. Following the wash in PBS, the pellets were 
resuspended in 50 µl of buffer solution and were incubated 
in 10 µl of Muse Hu IgG1-PE or Muse Hu Ki67-PE for 30 
min at room temperature and protected from light exposure. 
After 150 µl of Muse assay buffer was added to each sample 
and mixed thoroughly, the samples were run on the Muse 
cell analyzer to separate and determine the percentages of 
Ki67-positive and Ki67-negative populations.
Angiogenesis antibody array: Passage 4–6 cells were cultured 
for 9 days in growth factor deprivation medium; 1.5 ml of 
supernatant from the clinical case 3 C-FVM was collected, 
and protein secretion was analyzed using the Human Angio-
genesis Antibody Array Kit (R&D Systems, Minneapolis, 
MN). The membrane, containing antibodies for 55 proteins 
related to angiogenesis, was immersed in 1.5 ml of 2:1 super-
natant and array buffer (included in the kit), as well as 15 µl 
of reconstituted antibody cocktail. Following incubation in 
blocking buffer for 1 h, the membrane was incubated over-
night on a rocking platform at 4 °C, washed three times for 
10 min, submerged in 2 ml of diluted streptavidin-horseradish 
peroxidase (HRP) in array buffer, and incubated for 30 min at 
room temperature. Following a rinse in the wash buffer, the 
membrane was coated with 1 ml of the chemireagent mix. 
Kodak BioMax light film (Cat. No. 1788207, Eastman Kodak 
Company, Rochester, NY) was placed over the membrane 
and allowed to sit in the dark for 30 min. The film was then 
processed and developed using a Kodak M35A film processor 
(Eastman Kodak Company) and scanned with an Epson 
Perfection V500 (Long Beach, CA) photo scanner.
ELISA measurement of angiopoietin-1, thrombospondin-1, 
PEDF, and endothelin-1: Quantitative comparison of 
angiopoietin-1 (Ang-1; R&D Systems), thrombospondin-1 
(Tsp-1; R&D Systems), pigment epithelium-derived factor 
(PEDF; Millipore, Temecula, CA), and endothelin-1 (ET-1; 
R&D Systems) protein in HRP control cells and C-FVMs 
cultured in different glucose concentrations and osmolarity 
was determined using enzyme-linked immunosorbent assay 
(ELISA). Cell-free supernatants from HRP control cells and 
the C-FVMs from clinical case 3 were collected 9 days after 
treatment with 5 mM, 15 mM, and 30 mM D-glucose and 
5 mM D-glucose plus 25 mM L-glucose (osmotic control).
Student t tests were used to evaluate differences in the 
Ang-1, Tsp-1, PEDF, and ET-1 protein levels under different 
glucose and osmolar conditions, and compared to the 5 
mM D-glucose group. p<0.05 was considered statistically 
significant. All values in the ELISA results are expressed as 
mean ± standard deviation.
RESULTS
Clinical demographics and case report: Eleven eyes from 11 
patients were enrolled in the study, and the demographic and 
clinical information for each patient is listed in Appendix 1. 
Clinical case 3 illustrates a typical case of a woman aged 29 
years with type 1 diabetes with combined tractional and rheg-
matogenous retinal detachment of the left eye (Figure 1A). 
Visual acuity was light perception in the right eye and 20/200 
in the left eye. The patient’s ocular history was significant 
for a previous macula involving tractional retinal detachment 
in the right eye that underwent vitrectomy surgery and the 
placement of silicone oil. The patient underwent vitrectomy 
with segmentation and delamination of FVM in the left eye 
with placement of non-expansile C3F8 gas. At post-operative 
month 3 (POM3), the patient developed a cataract in the left 
eye, and visual acuity was 20/100. At post-operative month 
5 (POM5), the patient underwent cataract surgery, and the 
retina remained attached with visual acuity of 20/25 (Figure 
1B). The FVM was delaminated and visualized under 
light microscopy (Figure 1C) and grossly appeared to be a 
combined neovascular-fibrotic membrane, as blood vessels 
were clearly visualized within the tissue (Figure 1C, inset). 
The C-FVMs were isolated as described in the Methods 
section, and in culture formed a monolayer of cells with 
fibroblastic and stellate morphology (Figure 1D).
Ultrastructural examination of FVMs: Consistent with 
previous reports, electron micrographic examination of the 
FVM tissue from clinical case 1 (Appendix 2, A,B) showed 
numerous blood vessels and vessel-like structures, large areas 
of fibrosis, and numerous scattered stromal cells, some with 
no clear association to vascular structures [34]. There were 
different types of vascular abnormalities (Appendix 2, C), 
including disorganized microvessels and irregular perivas-
cular cell investment (Appendix 2, D). Many of the vascular 
cells had large nuclei and plasma membrane infoldings. Some 
of the perivascular cells appeared to have swollen mitochon-
dria (Appendix 2, C). These morphological features are remi-
niscent of vascular cells from tumors, which have been shown 
to carry large chromosomal and centrosomal aberrations, an 
indication of genomic instability [35-37].
Genomic integrity of FVMs: In light of the ultrastructural 
abnormalities previously reported [34] and currently 
observed (Appendix 2) in cells from FVMs, we determined 
whether cells from FVMs carried genomic abnormalities 
characteristic of other proliferative conditions [36]. For this 
purpose, we compared DNA extracted from FVMs with DNA 
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extracted from the blood of the same donor using comparative 
genomic hybridization (CGH) analysis. This analysis, which 
was conducted on paired samples from five unrelated donors, 
indicated that cells from FVMs lack major somatic chromo-
somal abnormalities or aneuploidies (clinical cases 7–11).
We observed that different segmentation algorithms 
identified potential focal copy number variations (8.5 Kb to 
3.7 Mb, Appendix 3). The significance of this finding remains 
to be determined, although we also noted that the DNA 
amplification step that was required to conduct this analysis 
using limiting amounts of DNA from the FVM (approxi-
mately 50–70 ng, see Methods) is known to generate artifacts, 
especially for genes that contain repetitive sequences [38–40]. 
To address this issue, we conducted a single nucleotide 
polymorphism (SNP) array in one additional donor (clinical 
case 3) from which sufficient genomic DNA from the FVM 
was obtained for analysis, and thus, DNA amplification was 
not required. Again, large chromosomal aberrations were 
absent. This result differs from previous reports of large 
chromosomal aberrations and aneuploidies in vascular cells 
from tumors [35-37], another condition also characterized by 
aberrant neovascularization.
Immunohistological characterization of FVMs: To evaluate 
the identity of the cellular components, we examined FVMs 
from clinical cases 2–6 versus a control retina using immuno-
histochemistry. Staining of the control retina (Figure 2A–E) 
revealed expected staining of blood vessels with antisera 
against CD31 in endothelial cells and labeling for SMA in 
mural cells. Staining of glial cells within the nerve fiber layer 
for GFAP can be seen as the processes surrounding the blood 
vessels. Finally, RPE65 and BEST-1 staining localized to the 
RPE.
The staining patterns among the various FVMs were 
variable (Figure 2). Table 1 illustrates the number of nuclei 
per surface area of FVM for the total number of cells that 
were labeled for CD31, SMA, GFAP, and BEST-1 antibodies. 
No FVMs stained positively for RPE65. Cases 3 and 5 had the 
highest number of nuclei (188.17 and 151.62 nuclei/10 µm2, 
respectively). Further, these two cases also had the most 
CD31-positive (21.22 and 21.20 nuclei/10 µm2, respectively), 
SMA-positive (168.86 and 105.58 nuclei/10 µm2 respectively), 
and BEST-1-positive (87.99 and 50.81 nuclei/10 µm2, respec-
tively) cells. In contrast, cases 2 and 6 had moderate numbers 
of CD31-positive cells (7.78 and 12.83 nuclei/10 µm2, respec-
tively), and case 2 contained higher levels of SMA-positive 
Figure 1. Clinical case 3 repre-
senting combined tractional and 
rhegmatogenous retinal detach-
ment with resection of FVM and 
growth of C-FVM. Pre-operative 
fundus photograph of the left eye 
reveals combined tractional and 
rhegmatogenous retinal detach-
ment of the left eye with 20/200 
vision (A). FVM (outlined by dotted 
white line) involves the macula and 
reveals fibrous tissue with aber-
rant blood vessels. Post-operative 
fundus photograph five months 
post vitrectomy and one month 
after cataract surgery demonstrates 
re-attached retina with 20/25 vision 
(B). Bright field microscopy of 
surgically resected FVM shows 
fibrous tissues and blood vessels 
(C, inset). Bright field microscopy of cells derived from FVM reveals a morphologically heterogeneous mixture of fibroblastic and stellate 
cells (D). Scale bar = 100 µm. 
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Figure 2. Histopathological characterization of FVM tissue from patients with severe PDR. Light micrographs of the control retina (A–E) 
and fibrovascular membranes (FVMs) from five different cases (F–DD) processed for immunohistochemistry using primary antibodies 
against CD 31 (A, F, K, P, U, Z), smooth muscle actin (SMA, B, G, L, Q, V, AA), glial fibrillary acidic protein (GFAP, C, H, M, R, W, BB), 
retinal pigment epithelium-specific protein 65 (RPE65, D, I, N, S, X, CC), and bestrophin-1 (BEST-1, E, J, O, T, Y, DD; all in red) and 
counterstained with hematoxylin (blue). In the control retina, faint CD31 staining of endothelial cells is observed (A), SMA localization is 
restricted to vessels (B), GFAP staining localizes to cells surrounding the blood vessels within the nerve fiber layer (NFL, C), and RPE65 and 
BEST-1 localize to the RPE cells (D, E). For FVMs derived from different patients, however, there was notable variability in the localization 
patterns and the number of positive cells for the different markers. All FVMs have CD31-positive cells, which are perivascular (F, K, P, U, 
Z). SMA-positive cells were also detected in all FVMs; some SMA staining was localized predominately to cells surrounding the vessels 
(G, AA) whereas other SMA-positive cells appear to be stromal (L, Q, V), located throughout the fibrous tissue of the FVM. GFAP-positive 
cells are also observed in all FVMs; some GFAP-positive cells are seen surrounding vessels (H, BB) whereas other GFAP-positive cells 
are located within the stroma of the FVM (M, R, W). Whereas all FVMs are RPE65-negative (I, N, S, X, CC), BEST-1 positive cells are 
distributed throughout the FVM tissue, as well as localized to perivascular cells (J, O, T, Y, DD). Scale bar=100 µm.
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cells versus case 6 (51.44 and 10.82 nuclei/10 µm2, respec-
tively), and fewer GFAP-positive cells (6.93 and 51.58 
nuclei/10 µm2, respectively). Furthermore, the localization 
of SMA-positive cells differed between these two cases. In 
case 2, SMA-positive cells were found surrounding blood 
vessels as well as the stroma (Figure 2G), whereas in case 6, 
SMA-positive cells were found exclusively adjacent to blood 
vessels (Figure 2AA). In addition, the localization of GFAP-
positive cells was different between these two cases. In case 
2, GFAP-positive cells were localized around blood vessels 
(Figure 2H), whereas in case 6, GFAP-positive cells were 
surrounding blood vessels as well as the stroma (Figure 2BB). 
Cases 2 and 6 contained similar amounts of BEST-1-positive 
cells (24.3 and 30.43 nuclei/10 µm2, respectively) in associa-
tion with blood vessels (Figure 2J,DD). Case 4 had the fewest 
CD31-positive cells (1.36 nuclei/10 µm2), a moderate number 
of SMA-expressing cells (20.26 nuclei/10 µm2), no cells that 
were positive for GFAP, and the fewest BEST-1 positive cells 
(10.51 nuclei/10 µm2). These data indicate that quantification 
and localization of the specific cell markers vary extensively 
among FVMs removed from patients with PDR.
Isolation, cell culture, and characterization of C-FVMs: 
Having shown that cells from FVMs are a genetically homog-
enous population using CGH and that they express specific 
markers of cell identity, we then established methodologies 
for isolation and primary culture of the cells. Cells displaying 
mural cell, fibroblast, or stellate morphology were clearly 
identified, suggesting the presence of pericytes, myofibro-
blasts, and glial cell populations (Figure 1D).
To determine whether C-FVMs retained their pheno-
types in culture, we conducted immunohistochemistry 
analyses of tissue and of cells cultured from FVM fragments 
obtained from the same donor (Figure 3). SMA-positive cells 
were abundant in the FVM derived from clinical case 3 and 
were also detected in the C-FVMs derived from the same 
donor (Figure 3A,C). Other cell populations, including GFAP-
positive cells, were also identified in the cell culture (Figure 
3B,D). SMA-positive and GFAP-positive cells were identified 
in cells cultured from the FVM of case 5 (Figure 3E–H), 
indicating that the C-FVMs retain the expression of some 
markers expressed by cells in the tissue.
Cell proliferation analysis: FVMs from cases 3 and 5, which 
appeared to have the highest number of nuclei, gave rise to 
robust cultures that were expanded and stored. We examined 
Ki67 staining in FVM fragments from clinical case 3 and 5 
and found Ki67-positive cells in both FVMs (Figure 4A,B). 
Approximately 63% of the cells were Ki67-positive in the 
FVM from clinical case 3 and approximately 28% of the 
cells were Ki67-positive in the FVM from clinical case 5. 
Additionally, we used a microcapillary Muse cell analyzer to 
examine the Ki67-positive cells in the FVM-derived cultures 
and also observed a difference in percentage of Ki67-positive 
cells, as the culture of the cells from case 3 had more prolif-
erating cells (33.94%) in growth-factor rich media compared 
to the proliferation rate of cells from case 5 (18.40%; Figure 
4C,D). In contrast, in growth-factor reduced conditions, cases 
3 and 5 had roughly equivalent rates of cell proliferation with 
7.43% and 5.94% Ki67-positive cells, respectively (Figure 
4E,F). Our finding may indicate that cellular proliferation 
rates in vitro reflect cellular proliferation in situ with the 
FVMs themselves.
Isolation of CD31-positive C-FVMs: Isolectin B4 and 
CD31-positive cells were infrequently identified in the 
primary cultures (Figure 5A,B). This was unexpected because 
the CD31-positive cells were clearly identified lining vessels 
in the FVMs (Figure 5C). However, we reasoned that because 
the original culture after tissue digestion represented a mix of 
different cell populations, perhaps other cell populations were 
inhibiting the growth of the CD31-positive cells and taking 
over the culture. We have previously shown that coculture of 
endothelial cells with mural cells leads to the activation of 
transforming growth factor-β that limits the growth of endo-
thelial cells [41]. To avoid this limitation, CD31-positive cells 
were isolated using CD31 antibody coated Dynabeads imme-
diately before cell culture. The CD31-positive C-FVMs were 
maintained in laminin/collagen 1-coated culture dishes in the 
Table 1. CharaCTerisTiCs of fVMs reMoVed froM paTienTs wiTh diabeTes MelliTus.
Case No. Avg Nuclei/10 µm2 CD31+/10 µm2 SMA+/10 µm2 GFAP+/10 µm2 BEST-1+/10 µm2
2 69.790 7.782 51.441 6.926 24.303
3 188.171 21.223 168.861 1.591 87.994
4 51.606 1.361 20.263 0 10.507
5 151.615 21.200 105.582 3.665 50.810
6 47.599 12.826 10.822 51.578 30.433
BEST=bestrophin-1; CD31=cluster of differentiation 31; FVM=fibrovascular membrane; GFAP=glial fibrillary acidic protein; 
SMA=smooth muscle actin.
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Figure 3. Histopathological char-
acteristics of FVMs are retained in 
C-FVMs. Fibrovascular membranes 
(FVMs) from clinical cases 3 and 
5 were processed for immuno-
histochemistry using antibodies 
against SMA (A, E) and GFAP (B, 
F; all in red) and counterstained 
with hematoxylin (blue). Immuno-
fluorescence of the C-FVMs shows 
cells positive for SMA (C, G) and 
GFAP (D, H; in green), indicating 
that molecular markers of cell iden-
tity are retained in C-FVMs grown 
in vitro. Nuclei are counterstained 
with 4’,6-diamidino-2-phenylindole 
(DAPI; blue). Scale bar=50 µm.
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presence of 6 ng/ml VEGF (Figure 5D). Our data indicate that 
CD31-positive cells from FVM tissue can be cultured when 
selected at the time of initial isolation.
Profiling angiogenesis-related factors secreted by C-FVMs: 
An antibody array targeting 55 proteins was used to examine 
the angiogenesis-related factors secreted by the SMA-posi-
tive/CD31-negative C-FVMs in the primary culture from case 
3. Appendix 4 identifies the 55 angiogenesis-related proteins 
assayed with the human angiogenesis antibody array and 
gives their coordinates on the membrane. Of the 55 targeted 
proteins, 11 proteins were detected in the supernatants of 
cells derived from the case 3 FVM. The C-FVMs expressed 
angiogenin (ANG), Ang-1, ET-1, insulin-like growth factor 
binding proteins 2 and 3 (IGFBP-2 and IGPBP-3), monocyte 
chemoattractant protein-1 (MCP-1), plasminogen activator 
inhibitor-1 (PAI-1), pentraxin 3 (PTX-3), pigment epithelium-
derived factor (PEDF), TIMP metallopeptidase inhibitor 
1 (TIMP-1), and Tsp-1 (Figure 6A). To confirm that these 
secreted proteins are indeed being made by the C-FVMs, we 
looked at the mRNA expression levels of a subset of these 
proteins. Quantitative reverse transcription-PCR (RT-qPCR) 
confirmed the expression of Ang-1, ET-1, PEDF, and Tsp-1 
in the cultured SMA-positive/CD31-negative C-FVMs 
from clinical case 3 (Appendix 5). To examine whether the 
C-FVMs responded differentially to a diabetic environment, 
we cultured the SMA-positive/CD31-negative C-FVMs 
from case 3 in high-glucose or hyperosmolar conditions and 
measured the levels of secreted factors using ELISA. Since 
these C-FVMs were SMA-positive, we chose to compare 
them to primary retinal pericytes derived from a non-diabetic 
donor, a cell type that also expresses this cell marker [42,43]. 
High glucose or hyperosmolarity triggered a statistically 
significant decrease in the secretion of Ang-1 and Tsp-1 
(Figure 6B,C) but had no effect on PEDF or ET-1 secretion 
(Figure 6D,E). In contrast, under similar conditions, SMA-
positive human retinal pericytes derived from a non-diabetic 
donor showed no significant change in the secretion of these 
factors (Figure 6B-E).
Figure 4. Proliferative activity 
of C-FVMs var ies between 
different clinical cases. Fibrovas-
cular membranes (FVMs) from 
clinical cases 3 (A) and 5 (B) were 
processed for immunohistochem-
istry using antibodies against Ki67 
(in red) and counterstained with 
hematoxylin (blue). C-FVMs from 
clinical case 3 and clinical case 
5 differ in the percentage of cells 
that are Ki67-negative (66.06% 
versus 81.60%) and Ki67-positive 
(33.94% versus 18.40%) when 
cultured in growth media (C, D). 
The percentage of cells that are 
Ki67-negative (92.57% versus 
94.06%) and Ki67-positive (7.43% 
versus 5.94%) in C-FVMs from 
clinical cases 3 and 5 are similar 
under growth factor-starvation 
conditions (E, F). Scale bar=50 µm.
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DISCUSSION
In this work, we report the isolation, culture, and character-
ization of cells from FVMs or C-FVMs derived from patients 
with proliferative diabetic retinopathy, the most prevalent 
cause of vision loss in working-age adults in developed coun-
tries [44]. Parallel analyses in tissue and cell culture demon-
strate that C-FVMs in primary culture retain at least some 
cell identity markers found in their tissue of origin, secrete 
factors relevant to the regulation of angiogenesis, and may 
respond to high glucose or hyperosmolar conditions differ-
ently than cells derived from non-diabetic donors. Because 
C-FVMs are derived from a relevant pathological tissue and 
have been exposed to a diabetic environment for the duration 
of the disease, they may represent a unique tool for eluci-
dating the pathobiological mechanisms that underlie PDR.
We found that SMA-positive C-FVMs expressed several 
signaling molecules with angiogenic and antiangiogenic prop-
erties including ANG, Ang-1, IGFBP-2, IGPBP-3, MCP-1, 
PAI-1, PTX-3, PEDF, TIMP-1, Tsp-1, and ET-1. These results 
are consistent with previous reports on the secretion of angio-
genesis related factors by cells derived from FVMs [32] and 
suggest that these cells may be participants, not bystanders, 
in PDR pathology. In fact, we found that under conditions that 
mimic a diabetic environment (e.g., high glucose or hyperos-
molarity), C-FVMs secrete lower levels of Ang-1 and Tsp-1, 
factors that are involved in the stabilization and/or inhibition 
of angiogenesis [45-47], compared to cells from a non-
diabetic donor. These results suggest that the use of C-FVMs 
for analyzing phenotypic changes induced by diabetes may 
be more relevant than retinal vascular cells derived from non-
diabetic sources, which are the current standard in the field. 
Whether somatic mutations arising in situ play a role in the 
proliferative phenotype of cells from FVMs requires further 
investigation, although our CGH studies indicate that, unlike 
vascular cells from tumors [35-37], cells from FVMs lack 
major chromosomal and centrosomal anomalies.
The Ang1-Tie2 system is involved in endothelial-
stromal cell interactions and regulates vascular maturation 
and stability [48,49]. Overexpression of Ang1 has also been 
found to block the permeability-inducing effects of VEGF 
in vivo and, thus, has been proposed as a therapeutic option 
for the treatment of aberrant neovascularization in the eye 
[46,50]. High levels of Ang1 were found in patients with 
non-proliferative DR when compared to patients with PDR 
[51]. Consistent with this observation, C-FVMs cultured in 
high-glucose or hyperosmolar conditions had reduced Ang1 
expression, which may contribute to vascular instability in 
PDR. Similarly, C-FVMs responded to high glucose or hyper-
osmolarity by decreasing the expression of Tsp-1, a potent 
endogenous inhibitor of angiogenesis [45,52]. Loss of Tsp-1 
in vitreous samples from diabetic rats has been associated 
with early retinopathy [5]. Consequently, downregulation of 
Figure 5. Isolation of CD31-positive 
cells from C-FVMs. Immunofluo-
rescence localization of isolectin 
(A) and CD31 (B) cells from clinical 
case 4 identifies rare positive cells. 
Fibrovascular membrane (FVM) 
from clinical case 5 processed 
for immunohistochemistry using 
antibodies against CD31 (red) and 
counterstained with hematoxylin 
(blue; C). Light micrographs of 
C-FVMs from clinical case 5 show 
isolation of CD31-positive cells, 
bound to CD31-antibody coated 
Dynabeads before cell culture (D). 
Scale bar=50 µm.
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Figure 6. Angiogenesis-related 
proteins secreted by C-FVMs: The 
effect of high glucose and hyperos-
molarity. Map of the human angio-
genesis antibody array targeting 
55 proteins related to angiogenesis 
and angiogenesis-related factors 
identified 11 proteins secreted by 
C-FVMs from clinical case 3 (A). 
For identity and coordinates of all 
55 proteins assayed, see Appendix 
4. Protein levels of (B) angiopoi-
etin-1, (C) thrombospondin-1, 
(D) PEDF, and (E) endothelin-1 
under different glucose treatments 
were measured in human retinal 
pericytes (HRP) and C-FVMs 
from clinical case 3 using an 
ELISA assay. Student t tests show 
there was a significant reduction 
in levels of angiopoietin-1 and 
thrombospondin-1 by cells grown 
in high glucose (30 mM D-glucose) 
and under hyperosmolar conditions 
(30 mM L-glucose), as compared to 
normal glucose and normal osmolar 
conditions (5 mM). No changes 
in PEDF or endothelin-1 protein 
levels were observed in C-FVMs in 
response to changes in glucose or 
osmolarity conditions. The levels of 
angiopoietin-1, thrombospondin-1, 
PEDF, and endothelin-1 did not 
in change in HRP in response to 
treatment with different glucose 
or osmolar conditions. Error bars 
represent ± standard deviations; 
**p<0.01; n=3.
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Tsp-1 within the diabetic environment may further contribute 
to aberrant angiogenesis.
We found no staining for RPE65 in FVMs. This result 
is in contrast with the suggestion that RPE cells migrate into 
FVMs or that RPE cells can migrate through retinal holes in 
combined tractional retinal detachment (TRD)/ rhegmatog-
enous retinal detachment (RRD) to invest FVMs within these 
patients [53]. Three out of five patients from whom the FVMs 
were obtained had concurrent rhegmatogenous retinal detach-
ment, which would presumably provide access for the RPE to 
the vitreous cavity. The absence of RPE65 staining suggests 
that, in contrast to the formation of epiretinal membranes 
in proliferative vitreoretinopathy, differentiated RPE cells 
may not play a significant role in the formation of the FVM, 
although we cannot rule out the possibility that RPE cells 
downregulate RPE65 expression as they undergo epithelial 
mesenchymal transition (EMT) [54,55]. Surprisingly, we 
found that bestrophin-1 was expressed in neovessels in 
all FVM samples evaluated with immunohistochemistry. 
Although bestrophin-1 in the eye is generally considered a 
marker of RPE cells, bestrophins have also been shown to 
be expressed in vascular smooth cells within the mesenteric 
arteries and function as an important regulator of vascular 
constriction [56]. The role of bestrophin-1 in neovessels 
within the setting of PDR has yet to be clarified; however, 
expression of bestrophin-1 in new vessels of FVMs has not 
previously been observed.
Ultimately, PDR is a disorder involving the progression 
of activities including cell migration into the vitreous, cell 
division, release of angiogenic factors, and generation of 
tractional forces. Identification of the cellular constituency 
of FVMs and the ability to establish these cells in culture is 
a step toward understanding the pathogenesis of late-stage 
PDR. Because almost 90% of patients with PDR have bilat-
eral disease at their primary examination [57] and because 
fibrovascular proliferation may relapse over time [58], it is 
common for patients undergo multiple surgical procedures to 
remove FVMs, and FVM specimens could be available from 
the same individual over a period of months to several years. 
In the future, we believe that the analysis of the cellular and 
molecular components of FVMs could provide information 
to allow for the discovery of novel cell signaling mechanisms 
linked to PDR.
APPENDIX 1. TABLE OF CLINICAL 
DEMOGRAPHICS AND PATIENT INFORMATION.
CF=counting fingers; CGH=comparative genomic hybrid-
ization; DM=diabetes mellitus; Dx=diagnosis; EM=electron 
microscopy; F=female; FVM=fibrovascular membrane; 
M=male; HM=hand motions; IHC=immunohistochemistry; 
LP=light perception; NA=not available; NV=neovascular; 
NVI=neovascularization of the iris; NVG=neovascular 
glaucoma; OD=right eye; OS=left eye; POM3=post-oper-
ative month 3; RRD=rhegmatogenous retinal detachment; 
SNP=single nucleotide polymorphism; TRD=tractional 
retinal detachment; Va=visual acuity; VH=vitreous hemor-
rhage. To access the data, click or select the words “Appendix 
1.”
APPENDIX 2. FVMS CONTAIN VESSELS WITH 
ABNORMAL VASCULAR MORPHOLOGY.
(A, B) Electron micrographs illustrate numerous blood vessels 
and vessel-like structures (black arrows), cells within the 
FVM stroma that are not associated with vascular structures 
(white arrows), as well as large areas of fibrosis (Fi) within a 
FVM resected from clinical case 1. Ultrastructural analysis 
reveals vessels with varying degrees of vascular abnormali-
ties (C and D), with multiple intercellular junctions between 
endothelial cells (black arrows), irregular perivascular cell 
investment (P), swollen mitochondria (*), and abnormal 
plasma membrane infoldings (white arrowheads). n=nucleus, 
Lu=Lumen. Scale bars: (A, B)=10 µm; (C, D)=2 µm. To 
access the data, click or select the words “Appendix 2.”
APPENDIX 3. TABLE OF COPY NUMBER 
VARIATIONS OF GENOMIC DNA FROM PAIRED 
SAMPLES OF FVM AND BLOOD.
Amp=amplification; bps=base pairs; Chr=chromosome; 
Del=deletion. To access the data, click or select the words 
“Appendix 3.”
APPENDIX 4. TABLE OF IDENTITY AND 
COORDINATES OF THE 55 PROTEINS IN THE 
HUMAN ANGIOGENESIS ANTIBODY ARRAY.
To access the data, click or select the words “Appendix 4.”
APPENDIX 5. MRNA EXPRESSION LEVELS OF 
ANGIOGENESIS-RELATED GENES IN C-FVM.
Expression of angiopoietin-1, thrombospondin-1, PEDF, and 
endothelin-1 was detected in C-FVM from clinical case 3 
by RT-qPCR. Error bars represent ± standard deviation. To 
access the data, click or select the words “Appendix 5.”
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